Skip to Main Content

Paper Details

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration.
Crit Care Med
62
2018
Author NameAffiliation
Nuala J MeyerUniversity of Pennsylvania Perelman School of Medicine
Michael G S ShashatyUniversity of Pennsylvania Perelman School of Medicine
Jason D ChristieUniversity of Pennsylvania Perelman School of Medicine
Jason D ChristieCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Steven M OpalMemorial Hospital of Rhode Island, the Alpert Medical School of Brown University
  • 1 - 5

Datasets